| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emphysema | 12 | 2024 | 67 | 5.070 |
Why?
|
| Lung | 43 | 2025 | 1491 | 4.720 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 23 | 2025 | 604 | 4.530 |
Why?
|
| Pulmonary Emphysema | 12 | 2024 | 93 | 3.960 |
Why?
|
| Cigarette Smoking | 8 | 2025 | 59 | 2.810 |
Why?
|
| Th17 Cells | 10 | 2024 | 90 | 2.560 |
Why?
|
| Smoking | 17 | 2020 | 1049 | 2.480 |
Why?
|
| Asthma | 25 | 2019 | 756 | 2.250 |
Why?
|
| Lung Neoplasms | 11 | 2025 | 1654 | 2.040 |
Why?
|
| Electronic Nicotine Delivery Systems | 4 | 2022 | 53 | 1.700 |
Why?
|
| Immunity, Innate | 14 | 2023 | 372 | 1.660 |
Why?
|
| Smoke | 11 | 2025 | 61 | 1.630 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2025 | 348 | 1.590 |
Why?
|
| Orthomyxoviridae Infections | 3 | 2025 | 59 | 1.550 |
Why?
|
| Influenza A virus | 2 | 2025 | 138 | 1.390 |
Why?
|
| Soot | 3 | 2022 | 15 | 1.330 |
Why?
|
| Interleukin-17 | 6 | 2024 | 121 | 1.280 |
Why?
|
| Matrix Metalloproteinase 2 | 9 | 2011 | 95 | 1.240 |
Why?
|
| Lung Diseases | 7 | 2018 | 385 | 1.230 |
Why?
|
| Antigen-Presenting Cells | 6 | 2019 | 118 | 1.230 |
Why?
|
| Th2 Cells | 21 | 2021 | 185 | 1.210 |
Why?
|
| Mice | 65 | 2025 | 17739 | 1.180 |
Why?
|
| Animals | 86 | 2025 | 34303 | 1.150 |
Why?
|
| Autoimmunity | 5 | 2019 | 172 | 1.080 |
Why?
|
| Hypersensitivity | 12 | 2022 | 185 | 1.060 |
Why?
|
| DNA Cleavage | 2 | 2017 | 6 | 1.040 |
Why?
|
| Dendritic Cells | 9 | 2023 | 414 | 1.040 |
Why?
|
| Peptide Hydrolases | 12 | 2019 | 145 | 1.010 |
Why?
|
| T-Lymphocytes | 6 | 2020 | 1720 | 0.990 |
Why?
|
| Disease Models, Animal | 27 | 2025 | 4407 | 0.990 |
Why?
|
| Macrophages, Alveolar | 6 | 2025 | 49 | 0.990 |
Why?
|
| Cytokines | 14 | 2023 | 1292 | 0.970 |
Why?
|
| Mycoses | 9 | 2023 | 118 | 0.950 |
Why?
|
| Mice, Inbred C57BL | 29 | 2025 | 4416 | 0.950 |
Why?
|
| Neuraminidase | 1 | 2025 | 36 | 0.930 |
Why?
|
| Plasma Cells | 1 | 2025 | 53 | 0.920 |
Why?
|
| Antigens, Neoplasm | 2 | 2025 | 384 | 0.910 |
Why?
|
| Allergens | 15 | 2018 | 252 | 0.910 |
Why?
|
| Matrix Metalloproteinases | 3 | 2017 | 65 | 0.870 |
Why?
|
| Matrix Metalloproteinase 9 | 9 | 2019 | 139 | 0.860 |
Why?
|
| Inflammation | 12 | 2023 | 1447 | 0.820 |
Why?
|
| Respiratory Hypersensitivity | 8 | 2019 | 52 | 0.800 |
Why?
|
| Elastin | 2 | 2019 | 31 | 0.790 |
Why?
|
| Pulmonary Alveoli | 8 | 2021 | 134 | 0.780 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2025 | 771 | 0.780 |
Why?
|
| Th1 Cells | 5 | 2012 | 153 | 0.770 |
Why?
|
| Mice, Knockout | 23 | 2020 | 3756 | 0.750 |
Why?
|
| Respiratory Mucosa | 7 | 2021 | 91 | 0.740 |
Why?
|
| Lymphocyte Activation | 9 | 2021 | 700 | 0.730 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2019 | 471 | 0.720 |
Why?
|
| Humans | 101 | 2025 | 125116 | 0.720 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 113 | 0.720 |
Why?
|
| Neoplasm Proteins | 2 | 2025 | 682 | 0.710 |
Why?
|
| Influenza, Human | 2 | 2025 | 662 | 0.670 |
Why?
|
| Complement C1q | 1 | 2019 | 19 | 0.640 |
Why?
|
| Tobacco Products | 4 | 2020 | 61 | 0.600 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2018 | 157 | 0.590 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 29 | 0.570 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 1023 | 0.560 |
Why?
|
| Respiratory Function Tests | 2 | 2024 | 198 | 0.560 |
Why?
|
| Adaptive Immunity | 4 | 2022 | 89 | 0.560 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2021 | 80 | 0.550 |
Why?
|
| Pneumonia | 6 | 2022 | 325 | 0.550 |
Why?
|
| Disease Progression | 9 | 2024 | 2084 | 0.540 |
Why?
|
| Wound Healing | 3 | 2017 | 457 | 0.540 |
Why?
|
| Fibrinogen | 5 | 2019 | 156 | 0.530 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 356 | 0.530 |
Why?
|
| Aspergillus niger | 6 | 2021 | 20 | 0.530 |
Why?
|
| Toll-Like Receptor 4 | 6 | 2023 | 138 | 0.520 |
Why?
|
| Vaping | 3 | 2022 | 30 | 0.510 |
Why?
|
| Peripheral Tolerance | 1 | 2015 | 4 | 0.500 |
Why?
|
| Osteopontin | 2 | 2014 | 49 | 0.490 |
Why?
|
| Nanoparticles | 2 | 2015 | 230 | 0.480 |
Why?
|
| Receptors, Complement | 2 | 2014 | 32 | 0.480 |
Why?
|
| Glycosphingolipids | 1 | 2015 | 11 | 0.480 |
Why?
|
| Mass Spectrometry | 2 | 2018 | 335 | 0.460 |
Why?
|
| Epoxide Hydrolases | 1 | 2014 | 37 | 0.450 |
Why?
|
| Bronchoalveolar Lavage Fluid | 8 | 2018 | 149 | 0.440 |
Why?
|
| Signal Transduction | 10 | 2016 | 4597 | 0.440 |
Why?
|
| Fungal Proteins | 6 | 2023 | 134 | 0.430 |
Why?
|
| Immunity | 4 | 2025 | 192 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 669 | 0.430 |
Why?
|
| PPAR gamma | 1 | 2014 | 88 | 0.430 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 82 | 0.420 |
Why?
|
| Biomarkers | 7 | 2022 | 3105 | 0.420 |
Why?
|
| Inhalation Exposure | 3 | 2021 | 36 | 0.420 |
Why?
|
| Metalloendopeptidases | 3 | 2002 | 101 | 0.420 |
Why?
|
| Bronchial Hyperreactivity | 4 | 2021 | 38 | 0.410 |
Why?
|
| Proteomics | 5 | 2024 | 506 | 0.400 |
Why?
|
| Airway Obstruction | 4 | 2017 | 165 | 0.400 |
Why?
|
| Interleukins | 2 | 2013 | 120 | 0.390 |
Why?
|
| Serine Endopeptidases | 3 | 2021 | 182 | 0.390 |
Why?
|
| Fungi | 4 | 2018 | 69 | 0.380 |
Why?
|
| Interleukin-4 | 9 | 2018 | 140 | 0.380 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 566 | 0.380 |
Why?
|
| Cell Differentiation | 7 | 2024 | 1910 | 0.380 |
Why?
|
| Sinusitis | 4 | 2021 | 116 | 0.370 |
Why?
|
| Extracellular Matrix | 4 | 2018 | 239 | 0.370 |
Why?
|
| CD11b Antigen | 2 | 2023 | 36 | 0.370 |
Why?
|
| Female | 42 | 2024 | 66709 | 0.360 |
Why?
|
| Cells, Cultured | 11 | 2019 | 3044 | 0.350 |
Why?
|
| Interferon-gamma | 7 | 2023 | 505 | 0.350 |
Why?
|
| Gene Expression Regulation | 7 | 2014 | 2527 | 0.350 |
Why?
|
| Rhinovirus | 1 | 2010 | 59 | 0.340 |
Why?
|
| Down-Regulation | 3 | 2024 | 692 | 0.330 |
Why?
|
| Picornaviridae Infections | 1 | 2010 | 48 | 0.330 |
Why?
|
| Macrophages | 5 | 2022 | 626 | 0.330 |
Why?
|
| Cysteine Endopeptidases | 1 | 2010 | 114 | 0.330 |
Why?
|
| Tobacco Smoking | 2 | 2020 | 19 | 0.320 |
Why?
|
| Immune Tolerance | 3 | 2019 | 144 | 0.320 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2009 | 21 | 0.320 |
Why?
|
| Immunoglobulin E | 5 | 2014 | 162 | 0.310 |
Why?
|
| Rhinitis | 3 | 2021 | 38 | 0.310 |
Why?
|
| Respiratory System | 7 | 2021 | 97 | 0.310 |
Why?
|
| Antifungal Agents | 3 | 2021 | 291 | 0.310 |
Why?
|
| Transcriptome | 4 | 2021 | 978 | 0.310 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 2 | 2021 | 19 | 0.310 |
Why?
|
| Tretinoin | 1 | 2009 | 118 | 0.300 |
Why?
|
| Pneumococcal Infections | 1 | 2011 | 275 | 0.300 |
Why?
|
| Lung Diseases, Fungal | 2 | 2019 | 32 | 0.300 |
Why?
|
| Epithelial Cells | 5 | 2021 | 909 | 0.300 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 376 | 0.300 |
Why?
|
| Viral Proteins | 1 | 2010 | 347 | 0.300 |
Why?
|
| Pulmonary Aspergillosis | 2 | 2021 | 11 | 0.290 |
Why?
|
| Gene Expression Profiling | 6 | 2024 | 1757 | 0.290 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2008 | 16 | 0.290 |
Why?
|
| Aspergillus | 4 | 2019 | 27 | 0.290 |
Why?
|
| Respiratory Tract Infections | 2 | 2022 | 274 | 0.290 |
Why?
|
| Chemokines, CC | 3 | 2005 | 28 | 0.290 |
Why?
|
| Interleukin-13 | 8 | 2017 | 97 | 0.290 |
Why?
|
| Nicotine | 2 | 2019 | 143 | 0.280 |
Why?
|
| Lung Injury | 2 | 2020 | 121 | 0.280 |
Why?
|
| Candida albicans | 3 | 2023 | 76 | 0.270 |
Why?
|
| MicroRNAs | 3 | 2024 | 858 | 0.270 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2019 | 217 | 0.260 |
Why?
|
| Male | 32 | 2024 | 61448 | 0.260 |
Why?
|
| Complement C3a | 3 | 2015 | 19 | 0.260 |
Why?
|
| Coculture Techniques | 2 | 2019 | 229 | 0.260 |
Why?
|
| Anesthesia, General | 3 | 2015 | 118 | 0.260 |
Why?
|
| Homeostasis | 3 | 2019 | 704 | 0.250 |
Why?
|
| Middle Aged | 20 | 2024 | 26682 | 0.250 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3422 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 396 | 0.250 |
Why?
|
| Cell Movement | 7 | 2018 | 854 | 0.250 |
Why?
|
| Sarcoidosis | 2 | 2023 | 61 | 0.240 |
Why?
|
| Immunotherapy | 3 | 2021 | 678 | 0.240 |
Why?
|
| Aged | 18 | 2021 | 19661 | 0.240 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 205 | 0.240 |
Why?
|
| ErbB Receptors | 3 | 2020 | 284 | 0.240 |
Why?
|
| Image-Guided Biopsy | 2 | 2015 | 38 | 0.240 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2025 | 9 | 0.240 |
Why?
|
| Bronchi | 4 | 2021 | 99 | 0.240 |
Why?
|
| Microglia | 2 | 2023 | 102 | 0.240 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 253 | 0.230 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2015 | 65 | 0.230 |
Why?
|
| Spores, Fungal | 3 | 2021 | 14 | 0.230 |
Why?
|
| Conscious Sedation | 2 | 2015 | 58 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2006 | 173 | 0.230 |
Why?
|
| Case-Control Studies | 6 | 2019 | 3310 | 0.230 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2024 | 10 | 0.220 |
Why?
|
| Adult | 18 | 2024 | 29465 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 199 | 0.220 |
Why?
|
| Bronchitis, Chronic | 1 | 2024 | 18 | 0.220 |
Why?
|
| Lymphadenopathy | 1 | 2024 | 30 | 0.220 |
Why?
|
| Immunophenotyping | 2 | 2018 | 327 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 1095 | 0.210 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 256 | 0.210 |
Why?
|
| Body Fluids | 1 | 2024 | 47 | 0.210 |
Why?
|
| Phenotype | 8 | 2024 | 4271 | 0.210 |
Why?
|
| Severity of Illness Index | 6 | 2022 | 2907 | 0.210 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 300 | 0.210 |
Why?
|
| Lymph Nodes | 2 | 2015 | 378 | 0.210 |
Why?
|
| Neutrophils | 2 | 2019 | 381 | 0.210 |
Why?
|
| Cell Proliferation | 4 | 2019 | 2377 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2024 | 129 | 0.200 |
Why?
|
| Veterans | 2 | 2024 | 1715 | 0.200 |
Why?
|
| Collagenases | 2 | 2001 | 18 | 0.200 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 3403 | 0.200 |
Why?
|
| Mice, Transgenic | 6 | 2016 | 2414 | 0.200 |
Why?
|
| Carbon | 1 | 2022 | 91 | 0.190 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2022 | 28 | 0.190 |
Why?
|
| Candidiasis | 2 | 2021 | 128 | 0.190 |
Why?
|
| Particulate Matter | 1 | 2022 | 70 | 0.190 |
Why?
|
| Disintegrins | 1 | 2002 | 13 | 0.190 |
Why?
|
| Reactive Oxygen Species | 2 | 2011 | 495 | 0.190 |
Why?
|
| Endopeptidases | 1 | 2002 | 116 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2022 | 509 | 0.190 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2021 | 4 | 0.190 |
Why?
|
| Blood | 1 | 2021 | 100 | 0.180 |
Why?
|
| Blood Chemical Analysis | 1 | 2021 | 81 | 0.180 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 1704 | 0.180 |
Why?
|
| Heterografts | 1 | 2021 | 175 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2002 | 102 | 0.180 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 21 | 0.170 |
Why?
|
| Furin | 1 | 2020 | 7 | 0.170 |
Why?
|
| Amino Acid Transport System y+L | 1 | 2020 | 17 | 0.170 |
Why?
|
| Neoplasm Transplantation | 1 | 2021 | 384 | 0.170 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2022 | 149 | 0.170 |
Why?
|
| Smoking Cessation | 1 | 2022 | 198 | 0.170 |
Why?
|
| Antigens, Fungal | 4 | 2014 | 34 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 320 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2025 | 503 | 0.170 |
Why?
|
| Models, Theoretical | 1 | 2022 | 363 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 205 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2023 | 505 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 54 | 0.170 |
Why?
|
| Antibodies, Fungal | 2 | 2014 | 13 | 0.160 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 297 | 0.160 |
Why?
|
| Threonine | 1 | 2019 | 60 | 0.160 |
Why?
|
| Oxidative Stress | 1 | 2025 | 818 | 0.160 |
Why?
|
| Leishmania major | 4 | 2013 | 27 | 0.160 |
Why?
|
| Solvents | 1 | 2019 | 44 | 0.160 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 124 | 0.160 |
Why?
|
| Dust | 3 | 2024 | 18 | 0.160 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2020 | 101 | 0.160 |
Why?
|
| Proline | 1 | 2019 | 77 | 0.160 |
Why?
|
| Leukocyte Elastase | 2 | 2019 | 19 | 0.160 |
Why?
|
| Matrix Metalloproteinase 12 | 2 | 2019 | 14 | 0.160 |
Why?
|
| Mucus | 3 | 2018 | 36 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 8 | 2013 | 1000 | 0.160 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 103 | 0.160 |
Why?
|
| Phospholipids | 1 | 2019 | 105 | 0.160 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 137 | 0.160 |
Why?
|
| Inflammation Mediators | 3 | 2022 | 246 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 327 | 0.150 |
Why?
|
| Blood Platelets | 1 | 2021 | 325 | 0.150 |
Why?
|
| Repressor Proteins | 2 | 2015 | 827 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2023 | 368 | 0.150 |
Why?
|
| Cerebrum | 1 | 2019 | 37 | 0.150 |
Why?
|
| B-Lymphocytes | 3 | 2024 | 532 | 0.150 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2009 | 42 | 0.150 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2018 | 34 | 0.150 |
Why?
|
| Neoplasms | 3 | 2021 | 2794 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 1534 | 0.150 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1997 | 27 | 0.150 |
Why?
|
| Glycine | 1 | 2019 | 168 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 505 | 0.150 |
Why?
|
| Candidemia | 1 | 2019 | 40 | 0.150 |
Why?
|
| Aspergillus oryzae | 3 | 2013 | 8 | 0.150 |
Why?
|
| Peptide Fragments | 3 | 2019 | 781 | 0.150 |
Why?
|
| Chemokine CXCL10 | 2 | 2011 | 53 | 0.150 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 361 | 0.150 |
Why?
|
| Cell Size | 1 | 1998 | 84 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 368 | 0.150 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 377 | 0.140 |
Why?
|
| Smad4 Protein | 1 | 2018 | 57 | 0.140 |
Why?
|
| Genes, T-Cell Receptor delta | 1 | 2017 | 8 | 0.140 |
Why?
|
| Prognosis | 6 | 2022 | 4684 | 0.140 |
Why?
|
| STAT6 Transcription Factor | 2 | 2015 | 35 | 0.140 |
Why?
|
| Leishmaniasis, Cutaneous | 3 | 2013 | 48 | 0.140 |
Why?
|
| Larynx | 1 | 2018 | 72 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 121 | 0.140 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 1694 | 0.140 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 179 | 0.140 |
Why?
|
| Nasal Polyps | 2 | 2014 | 25 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2025 | 1985 | 0.140 |
Why?
|
| Mutagens | 1 | 2017 | 84 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 1998 | 147 | 0.140 |
Why?
|
| Arginine | 1 | 2019 | 335 | 0.140 |
Why?
|
| Cell Line | 2 | 2019 | 2756 | 0.140 |
Why?
|
| Pleural Neoplasms | 1 | 2018 | 71 | 0.140 |
Why?
|
| Carcinogens | 1 | 2017 | 152 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 1275 | 0.130 |
Why?
|
| HEK293 Cells | 1 | 2019 | 738 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 3 | 2011 | 1130 | 0.130 |
Why?
|
| Mesothelioma | 1 | 2018 | 88 | 0.130 |
Why?
|
| Genes, erbB-1 | 1 | 2016 | 10 | 0.130 |
Why?
|
| Goblet Cells | 1 | 2017 | 103 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2014 | 63 | 0.130 |
Why?
|
| Memory Disorders | 1 | 2019 | 229 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 1033 | 0.130 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 151 | 0.130 |
Why?
|
| Smokers | 3 | 2022 | 40 | 0.130 |
Why?
|
| Phagocytosis | 2 | 2011 | 171 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 260 | 0.130 |
Why?
|
| Peptides | 1 | 2019 | 812 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2019 | 433 | 0.130 |
Why?
|
| Pandemics | 2 | 2020 | 1112 | 0.120 |
Why?
|
| Chemokines | 2 | 2014 | 134 | 0.120 |
Why?
|
| Peptidomimetics | 1 | 2015 | 12 | 0.120 |
Why?
|
| CD11a Antigen | 2 | 2013 | 12 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 465 | 0.120 |
Why?
|
| Phagocytes | 1 | 2015 | 23 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 33 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 1997 | 183 | 0.120 |
Why?
|
| Enzyme Activation | 3 | 2002 | 626 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2018 | 627 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 705 | 0.120 |
Why?
|
| Immunologic Memory | 2 | 2014 | 190 | 0.120 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 62 | 0.120 |
Why?
|
| Autocrine Communication | 1 | 2014 | 28 | 0.120 |
Why?
|
| Intestines | 1 | 2019 | 577 | 0.120 |
Why?
|
| Complement C3 | 1 | 2014 | 49 | 0.120 |
Why?
|
| Complement Activation | 1 | 2014 | 52 | 0.110 |
Why?
|
| Leukotrienes | 1 | 2014 | 7 | 0.110 |
Why?
|
| Exercise Test | 1 | 2015 | 254 | 0.110 |
Why?
|
| Paracrine Communication | 1 | 2014 | 69 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2015 | 1017 | 0.110 |
Why?
|
| Eosinophils | 4 | 2021 | 120 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 112 | 0.110 |
Why?
|
| DNA Damage | 1 | 2017 | 516 | 0.110 |
Why?
|
| Ovalbumin | 3 | 2005 | 319 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 3 | 2021 | 381 | 0.110 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2014 | 34 | 0.110 |
Why?
|
| Antibodies, Viral | 2 | 2017 | 1150 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2023 | 360 | 0.110 |
Why?
|
| Proteolysis | 1 | 2014 | 172 | 0.110 |
Why?
|
| Inflammasomes | 1 | 2015 | 151 | 0.110 |
Why?
|
| Immunity, Mucosal | 2 | 2011 | 87 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 155 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 343 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1265 | 0.110 |
Why?
|
| Kidney | 1 | 2020 | 1360 | 0.110 |
Why?
|
| Chemokine CCL7 | 2 | 2004 | 7 | 0.110 |
Why?
|
| Chemokine CCL17 | 2 | 2004 | 9 | 0.110 |
Why?
|
| Monocyte Chemoattractant Proteins | 2 | 2004 | 8 | 0.110 |
Why?
|
| Chemokine CCL11 | 2 | 2004 | 12 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 1066 | 0.100 |
Why?
|
| Tracheitis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Mycosis Fungoides | 1 | 2012 | 14 | 0.100 |
Why?
|
| Bronchitis | 1 | 2012 | 34 | 0.100 |
Why?
|
| Chemotaxis | 2 | 2003 | 58 | 0.100 |
Why?
|
| Status Asthmaticus | 1 | 2012 | 20 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 549 | 0.100 |
Why?
|
| NF-kappa B | 4 | 2019 | 462 | 0.100 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2010 | 22 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2022 | 6123 | 0.100 |
Why?
|
| Antigens, CD1 | 1 | 2012 | 21 | 0.100 |
Why?
|
| Fibroblasts | 3 | 2002 | 887 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1319 | 0.090 |
Why?
|
| Glycoproteins | 2 | 2004 | 367 | 0.090 |
Why?
|
| Dipeptides | 2 | 2002 | 56 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2018 | 1505 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2020 | 874 | 0.090 |
Why?
|
| Pyruvic Acid | 1 | 2011 | 38 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2011 | 57 | 0.090 |
Why?
|
| Calgranulin B | 2 | 2008 | 9 | 0.090 |
Why?
|
| beta-N-Acetylhexosaminidases | 2 | 2008 | 10 | 0.090 |
Why?
|
| Rest | 1 | 2011 | 58 | 0.090 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2019 | 662 | 0.090 |
Why?
|
| Lectins | 2 | 2008 | 54 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 53 | 0.090 |
Why?
|
| Forecasting | 2 | 2005 | 352 | 0.090 |
Why?
|
| Exome | 1 | 2016 | 1034 | 0.090 |
Why?
|
| Autophagy | 1 | 2014 | 395 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2017 | 1053 | 0.090 |
Why?
|
| Virus Replication | 3 | 2021 | 607 | 0.090 |
Why?
|
| Dermatitis, Atopic | 1 | 2011 | 41 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6541 | 0.080 |
Why?
|
| Genomics | 1 | 2018 | 1520 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2093 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1294 | 0.080 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2012 | 310 | 0.080 |
Why?
|
| Amyloid beta-Peptides | 2 | 2023 | 212 | 0.080 |
Why?
|
| Interleukin-1 | 2 | 2001 | 142 | 0.080 |
Why?
|
| Influenza Vaccines | 2 | 2014 | 480 | 0.080 |
Why?
|
| Retinal Dehydrogenase | 1 | 2009 | 11 | 0.080 |
Why?
|
| Aspergillus fumigatus | 3 | 2005 | 43 | 0.080 |
Why?
|
| Bronchoconstriction | 2 | 2021 | 17 | 0.080 |
Why?
|
| Environmental Exposure | 2 | 2024 | 220 | 0.080 |
Why?
|
| Receptor, Adenosine A3 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 14 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2021 | 1187 | 0.070 |
Why?
|
| Interleukin-1beta | 2 | 2019 | 163 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 343 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2008 | 36 | 0.070 |
Why?
|
| Integrins | 1 | 2008 | 97 | 0.070 |
Why?
|
| Tyrosine | 1 | 2008 | 151 | 0.070 |
Why?
|
| Proteins | 2 | 2011 | 1040 | 0.070 |
Why?
|
| Pulmonary Fibrosis | 1 | 2008 | 109 | 0.070 |
Why?
|
| Glucose | 1 | 2011 | 876 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2007 | 112 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2021 | 1708 | 0.070 |
Why?
|
| RNA, Messenger | 4 | 2021 | 2814 | 0.070 |
Why?
|
| Models, Biological | 4 | 2010 | 1465 | 0.070 |
Why?
|
| Betacoronavirus | 2 | 2020 | 290 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2006 | 1538 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2007 | 171 | 0.060 |
Why?
|
| Arylsulfonates | 1 | 2006 | 3 | 0.060 |
Why?
|
| Sulfonium Compounds | 1 | 2006 | 4 | 0.060 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2006 | 15 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2011 | 765 | 0.060 |
Why?
|
| Relaxin | 1 | 2006 | 15 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2006 | 43 | 0.060 |
Why?
|
| Anti-Allergic Agents | 1 | 2006 | 27 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 115 | 0.060 |
Why?
|
| Omalizumab | 1 | 2006 | 33 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 114 | 0.060 |
Why?
|
| Fibronectins | 2 | 1996 | 110 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 2182 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 5169 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 143 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 1284 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2007 | 265 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3176 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2005 | 88 | 0.060 |
Why?
|
| Macrophage Activation | 2 | 2016 | 64 | 0.060 |
Why?
|
| Desmosomes | 1 | 2004 | 7 | 0.060 |
Why?
|
| Proteome | 1 | 2006 | 246 | 0.060 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 21 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 1095 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2006 | 99 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 38 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 45 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 37 | 0.060 |
Why?
|
| Spirometry | 1 | 2024 | 73 | 0.060 |
Why?
|
| Epidermis | 1 | 2004 | 63 | 0.060 |
Why?
|
| Antibodies | 1 | 2006 | 374 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2005 | 793 | 0.060 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2025 | 114 | 0.060 |
Why?
|
| Gases | 1 | 2024 | 16 | 0.060 |
Why?
|
| CD18 Antigens | 1 | 2003 | 50 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2006 | 296 | 0.050 |
Why?
|
| Rabbits | 3 | 2001 | 718 | 0.050 |
Why?
|
| Ambrosia | 1 | 2002 | 14 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 170 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 413 | 0.050 |
Why?
|
| Leukocytes | 1 | 2004 | 212 | 0.050 |
Why?
|
| Dyspnea | 1 | 2024 | 153 | 0.050 |
Why?
|
| Immune System Diseases | 1 | 2003 | 47 | 0.050 |
Why?
|
| Pollen | 1 | 2002 | 46 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2023 | 116 | 0.050 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2002 | 3 | 0.050 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2002 | 17 | 0.050 |
Why?
|
| Splenomegaly | 1 | 2022 | 33 | 0.050 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2002 | 7 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2002 | 125 | 0.050 |
Why?
|
| Troponin | 1 | 2022 | 77 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 35 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 120 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2002 | 132 | 0.050 |
Why?
|
| Yersinia | 1 | 2001 | 5 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2022 | 173 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2012 | 239 | 0.050 |
Why?
|
| Synovial Membrane | 1 | 2001 | 27 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 113 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2002 | 154 | 0.050 |
Why?
|
| Computers | 1 | 2021 | 68 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 96 | 0.050 |
Why?
|
| Adolescent | 1 | 2019 | 19419 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 66 | 0.050 |
Why?
|
| Adhesins, Bacterial | 1 | 2001 | 75 | 0.040 |
Why?
|
| Risk Factors | 3 | 2022 | 10282 | 0.040 |
Why?
|
| A549 Cells | 1 | 2021 | 44 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2002 | 120 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2002 | 212 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 261 | 0.040 |
Why?
|
| Aspirin | 1 | 2002 | 222 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2013 | 802 | 0.040 |
Why?
|
| Monocytes | 1 | 2023 | 345 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2021 | 93 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 393 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2020 | 43 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 664 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 402 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 133 | 0.040 |
Why?
|
| American Heart Association | 1 | 2022 | 322 | 0.040 |
Why?
|
| Research Report | 1 | 2020 | 75 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 304 | 0.040 |
Why?
|
| Receptors, IgE | 1 | 1999 | 10 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 81 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 537 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1026 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2021 | 16342 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 118 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 682 | 0.040 |
Why?
|
| Protein Binding | 2 | 2019 | 1756 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 168 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 780 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 174 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2011 | 108 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1035 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2019 | 76 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 473 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 365 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2019 | 165 | 0.040 |
Why?
|
| Receptors, Fibronectin | 1 | 1998 | 8 | 0.040 |
Why?
|
| Cytochalasin D | 1 | 1998 | 12 | 0.040 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 6 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2019 | 171 | 0.040 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 1998 | 24 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 914 | 0.040 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 18 | 0.040 |
Why?
|
| rac GTP-Binding Proteins | 1 | 1998 | 26 | 0.040 |
Why?
|
| Free Radicals | 1 | 1998 | 37 | 0.040 |
Why?
|
| Pleura | 1 | 2018 | 25 | 0.040 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2019 | 126 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1605 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 236 | 0.040 |
Why?
|
| Chemical Warfare | 1 | 2017 | 1 | 0.040 |
Why?
|
| Plethysmography | 1 | 2018 | 35 | 0.040 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2017 | 4 | 0.040 |
Why?
|
| Mustard Gas | 1 | 2017 | 5 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 492 | 0.040 |
Why?
|
| Airway Remodeling | 1 | 2017 | 21 | 0.040 |
Why?
|
| Butanones | 1 | 2017 | 7 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 24 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 1998 | 112 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 19 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 475 | 0.040 |
Why?
|
| Nitrosamines | 1 | 2017 | 19 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1996 | 1243 | 0.040 |
Why?
|
| Exons | 1 | 2020 | 802 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 235 | 0.040 |
Why?
|
| Amino Acids | 1 | 2020 | 668 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 477 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 251 | 0.040 |
Why?
|
| Sputum | 1 | 2018 | 106 | 0.040 |
Why?
|
| Azacitidine | 1 | 2017 | 54 | 0.030 |
Why?
|
| Bronchial Provocation Tests | 2 | 2010 | 14 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 688 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2018 | 174 | 0.030 |
Why?
|
| Proteogenomics | 1 | 2018 | 69 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 79 | 0.030 |
Why?
|
| United States | 2 | 2024 | 10884 | 0.030 |
Why?
|
| DNA Adducts | 1 | 2017 | 77 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 4822 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 153 | 0.030 |
Why?
|
| Apoptosis | 1 | 2004 | 1819 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 241 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1998 | 381 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 1997 | 47 | 0.030 |
Why?
|
| Clodronic Acid | 1 | 2016 | 4 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cetuximab | 1 | 2016 | 13 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 14 | 0.030 |
Why?
|
| Metaplasia | 1 | 2017 | 213 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 456 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 276 | 0.030 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2017 | 67 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 259 | 0.030 |
Why?
|
| Uteroglobin | 1 | 2016 | 46 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 819 | 0.030 |
Why?
|
| Exercise | 1 | 2002 | 814 | 0.030 |
Why?
|
| Cell Migration Inhibition | 2 | 2006 | 10 | 0.030 |
Why?
|
| Length of Stay | 1 | 2022 | 1306 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1496 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 798 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1997 | 170 | 0.030 |
Why?
|
| Carcinoma, Large Cell | 1 | 2016 | 9 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 887 | 0.030 |
Why?
|
| Astrocytes | 1 | 2019 | 251 | 0.030 |
Why?
|
| Salmeterol Xinafoate | 1 | 2015 | 13 | 0.030 |
Why?
|
| beta-Arrestins | 1 | 2015 | 30 | 0.030 |
Why?
|
| Arrestins | 1 | 2015 | 28 | 0.030 |
Why?
|
| Genotype | 1 | 2002 | 2570 | 0.030 |
Why?
|
| Formoterol Fumarate | 1 | 2015 | 31 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2011 | 1111 | 0.030 |
Why?
|
| Propanolamines | 1 | 2015 | 32 | 0.030 |
Why?
|
| Carbazoles | 1 | 2015 | 33 | 0.030 |
Why?
|
| Albuterol | 1 | 2015 | 52 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 84 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2015 | 109 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 291 | 0.030 |
Why?
|
| Integrin beta1 | 2 | 2008 | 56 | 0.030 |
Why?
|
| Blood Physiological Phenomena | 1 | 1994 | 5 | 0.030 |
Why?
|
| Seawater | 1 | 1994 | 12 | 0.030 |
Why?
|
| Blood-Air Barrier | 1 | 1994 | 4 | 0.030 |
Why?
|
| Metabolome | 1 | 2017 | 293 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 111 | 0.030 |
Why?
|
| Child | 3 | 2023 | 24614 | 0.030 |
Why?
|
| Endosonography | 1 | 2015 | 78 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3675 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2015 | 117 | 0.030 |
Why?
|
| Aquaporins | 1 | 1994 | 18 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 2014 | 42 | 0.030 |
Why?
|
| Body Water | 1 | 1994 | 90 | 0.030 |
Why?
|
| Mercury | 1 | 1994 | 29 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1994 | 123 | 0.030 |
Why?
|
| Rats | 3 | 1996 | 3728 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1784 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 362 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 422 | 0.030 |
Why?
|
| Interleukin-33 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2013 | 8 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2013 | 89 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2019 | 527 | 0.030 |
Why?
|
| Ion Channels | 1 | 1994 | 191 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 325 | 0.030 |
Why?
|
| Immunization | 1 | 2014 | 308 | 0.020 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 178 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2018 | 12273 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 347 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 544 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 734 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 538 | 0.020 |
Why?
|
| Ataxins | 1 | 2011 | 114 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2011 | 51 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 2717 | 0.020 |
Why?
|
| Radioactive Tracers | 1 | 2011 | 21 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 259 | 0.020 |
Why?
|
| Organogenesis | 1 | 2011 | 79 | 0.020 |
Why?
|
| Glycolysis | 1 | 2011 | 152 | 0.020 |
Why?
|
| Ataxin-1 | 1 | 2011 | 162 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1554 | 0.020 |
Why?
|
| Obesity | 1 | 2002 | 2244 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 363 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2010 | 31 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2011 | 277 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 3898 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1400 | 0.020 |
Why?
|
| Thy-1 Antigens | 1 | 2010 | 22 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 670 | 0.020 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2010 | 45 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 66 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2055 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 819 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 552 | 0.020 |
Why?
|
| Interleukin-5 | 1 | 2009 | 43 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 825 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2011 | 299 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 38 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2008 | 51 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 556 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3424 | 0.020 |
Why?
|
| Bleomycin | 1 | 2008 | 153 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 129 | 0.020 |
Why?
|
| Joints | 1 | 2007 | 23 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 369 | 0.020 |
Why?
|
| Calgranulin A | 1 | 2006 | 5 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 309 | 0.020 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2007 | 55 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2006 | 46 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 161 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 645 | 0.020 |
Why?
|
| Edema | 1 | 2007 | 136 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 5906 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2006 | 295 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2006 | 50 | 0.020 |
Why?
|
| Syndecans | 1 | 2005 | 4 | 0.020 |
Why?
|
| Syndecan-1 | 1 | 2005 | 7 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1997 | 3047 | 0.020 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2005 | 16 | 0.020 |
Why?
|
| Craniofacial Abnormalities | 1 | 2007 | 239 | 0.010 |
Why?
|
| Calcium | 1 | 2010 | 1105 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 132 | 0.010 |
Why?
|
| Serine Peptidase Inhibitor Kazal-Type 5 | 1 | 2004 | 3 | 0.010 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2004 | 6 | 0.010 |
Why?
|
| Bone Density | 1 | 2007 | 318 | 0.010 |
Why?
|
| Epithelium | 2 | 1996 | 365 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2006 | 271 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2004 | 150 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 657 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 768 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 283 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 1006 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 1018 | 0.010 |
Why?
|
| Fetus | 1 | 2006 | 586 | 0.010 |
Why?
|
| Munc18 Proteins | 1 | 2002 | 20 | 0.010 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2001 | 45 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2002 | 290 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 3109 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 1997 | 21 | 0.010 |
Why?
|
| Vinculin | 1 | 1996 | 4 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 1996 | 22 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1996 | 461 | 0.010 |
Why?
|
| Time Factors | 2 | 1996 | 6302 | 0.010 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 1994 | 2 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 780 | 0.010 |
Why?
|
| Extravascular Lung Water | 1 | 1994 | 2 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1994 | 30 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1994 | 74 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 176 | 0.010 |
Why?
|
| Aquaporin 1 | 1 | 1994 | 8 | 0.010 |
Why?
|
| Kinetics | 1 | 1996 | 1330 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1994 | 263 | 0.010 |
Why?
|
| Sheep | 1 | 1994 | 219 | 0.010 |
Why?
|
| Biological Transport | 1 | 1994 | 355 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1994 | 845 | 0.010 |
Why?
|